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Summary
 
The ability of influenza virus to evade immune surveillance by neutralizing antibodies (Abs) di-
rected against its variable surface antigens provides a challenge to the development of effective
 
vaccines. CD8
 
1
 
 cytotoxic T lymphocytes (CTLs) restricted by class I major histocompatibility
complex molecules are important in establishing immunity to influenza virus because they rec-
ognize internal viral proteins which are conserved between multiple viral strains. In contrast,
protective Abs are strain-specific. However, the precise role of effector CD8
 
1
 
 CTLs in protec-
tion from influenza virus infection, critical for understanding disease pathogenesis, has not been
well defined. In transgenic mice with a very high frequency of antiinfluenza CTL precursors,
but without protective Abs, CD8
 
1
 
 CTLs conferred protection against low dose viral challenge,
but exacerbated viral pathology and caused mortality at high viral dose. The data suggest a dual
role for CD8
 
1
 
 CTLs against influenza, which may present a challenge to the development of
effective CTL vaccines. Effector mechanisms used by CD8
 
1
 
 CTLs in orchestrating clearance of
virus and recovery from experimental influenza infection, or potentiation of lethal pathology,
are discussed.
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I
 
nfluenza A virus possesses the ability to modify its surface
antigens, hemagglutinin and neuraminidase (1–4), thereby
 
permitting sequential reinfections of the same host. Such
antigenic variation leads to worldwide epidemics and has
prevented control of disease by vaccines designed to induce
neutralizing Abs. The majority of CD8
 
1
 
 CTLs are directed
against conserved internal viral proteins such as nucleopro-
tein (NP)
 
1
 
 of influenza A virus. These CD8
 
1
 
 CTLs are
broadly cross-reactive, and recognize all major virus sub-
types (for a review, see references 5–8). Thus, much effort
has been directed towards development of a vaccine capa-
ble of inducing CD8
 
1
 
 CTL memory that recognizes pep-
tide epitopes of conserved viral proteins. Since replication
of mammalian influenza viruses is restricted to epithelial
cells of the respiratory tract, and systemic exposure of the
immune system to influenza consequently is limited (9, 10),
the contribution of CD8
 
1
 
 CTLs in primary antiviral re-
sponses is not inherently obvious. The recurrent nature of
influenza viral infections in humans (11) suggests that im-
munity mediated by CD8
 
1
 
 CTLs directed at conserved in-
ternal viral proteins is transient or only partially effective.
Thus, CTL memory cells, which occur in relatively high fre-
quency after influenza infection (6, 12–14), have marginal
impact on morbidity and mortality caused by reinfection with
heterosubtypic virus strains in humans (15–17). Observa-
tions on the role of CD8
 
1
 
 CTLs in heterosubtypic immu-
nity in animals give varying conclusions. Thus, virus-spe-
cific CD8
 
1
 
 CTLs protect against challenge with influenza
A infection in mice devoid of mature B cells and Abs (18–
20). Similarly, cloned CTLs specific for NP of influenza A
virus can passively transfer protection (21). On the other
hand, active immunization with recombinant NP or with
NP expressing vectors is only weakly protective (22–27).
In our studies, we have taken a new approach towards eval-
uation of the physiological features of CD8
 
1
 
 CTLs in influ-
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; i.n., intrana-
sal; MDCK, Madin-Darby canine kidney; NP, nucleoprotein; RAG-1
 
2
 
/
 
2
 
,
recombination activating gene 1–deficient; TCID50, 50% tissue culture in-
fectious dose; Tg, transgenic.
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enza infection. Tracking in situ CTL effector functions has
been technically challenging, due mainly to the very low fre-
quency and high TCR diversity of antigen-specific CTLs in
normal animals. To overcome this problem, we used trans-
genic (Tg) mice expressing a uniform type of 
 
ab
 
 TCR
heterodimer (
 
ab
 
4/
 
b
 
11; termed F5-Tg) derived from an
NP-specific T cell clone obtained from C57BL/10 mice (28,
29). The F5-Tg TCR recognizes the NP peptide (amino
acids 366–374) of influenza A virus A/NT/60/68 (H3N2)
presented by MHC-D
 
b
 
 class I molecules, and is expressed
in 
 
z
 
90% of peripheral T cells. Therefore, the mice possess
a high frequency of antiviral CTL precursor cells. By stain-
ing cells with Abs specific for V
 
b
 
11, CD8, and markers for
T cell activation, responsive Tg-CTLs can be identified and
characterized directly in situ. We demonstrate here that CD8
 
1
 
CTLs directed against the conserved NP of influenza A virus
in the absence of protective Abs can potently block viral repli-
cation in situ and either promote survival or exacerbate a lethal
influenza pneumonia. These results provide a clear demonstra-
tion that protection and pathology induced by antiviral CD8
 
1
 
CTLs represent different balance situations between a patho-
gen and the host’s immune system. This consideration is espe-
cially important in the lung, where disruption of lung structure
and pulmonary function can have devastating consequences.
 
Materials and Methods
 
Mice.
 
Mice transgenic or deficient for recombination activat-
ing gene 1 (RAG-1
 
2
 
/
 
2
 
) were maintained by breeding with
C57BL/10 (H-2
 
b
 
) mice under specific pathogen–free conditions.
F5-Tg mice were described previously (28, 29). RAG-1
 
2
 
/
 
2
 
 mice
were maintained by breeding with each other, or with F5-Tg in
order to obtain F5-Tg mice deficient for RAG-1 (30, 31). Ani-
mals were kept and experiments were performed in accordance
with the institutional animal welfare guidelines of the United
Kingdom and the United States.
 
Viruses.
 
Stock virus of influenza A/NT/60/68 (H3N2) virus
or the X31 (H3N2) reassortant influenza virus was grown in the
allantoic cavity of 10-d-old embryonated hen eggs, and were free
of bacterial, mycoplasma, and endotoxin contamination. X31 is a
reassortant virus with external virion proteins of A/Aichi/2/68
(H3N2) and the internal NP of A/PR/8/34 (H1N1). This reas-
sortant cannot be recognized by the Tg-CTLs due to alterations
(372D
 
®
 
E, 373A
 
®
 
T) within the relevant peptide epitope (32).
Virus was quantified in a plaque assay on Madin-Darby canine
kidney (MDCK) cells obtained from the American Type Culture
Collection (Rockville, MD; references 33 and 34).
 
Virus Titers in Lung Tissue.
 
Viral lung titers were determined
by 10-fold serial dilution of tissue extracts, and tested for infectivity
of MDCK cells in 96-well plates as detected by hemagglutinating
activity in the supernatants after a 48-h incubation at 37
 
8
 
C and 5%
CO
 
2
 
. Virus titers were estimated according the method of Reed
and Muench (35); the threshold of virus detection in the MDCK
assay is 10
 
2
 
 TCID50 (50% tissue culture infectious dose)/g lung tis-
sue. Lung extracts that were negative in the MDCK assay were
further tested by inoculation of 50 
 
m
 
l of undiluted extract in the
allantoic cavity of 10-d-old embryonated hen eggs; the threshold
of detection in this system was 
 
#
 
20 egg infectious doses per lung.
 
Detection of Antiviral Abs in Sera of Infected Mice.
 
The titer of
virus-specific Abs in serum was assayed by ELISA as described
 
previously (36). Sera of infected mice were tested on plates coated
with 1 
 
m
 
g of purified A/NT/60/68 or X31 influenza virus (37).
 
Flow Cytometry.
 
Cells isolated by bronchoalveolar lavage (BAL)
were stained directly with FITC- or PE-coupled reagents or indi-
rectly with biotinylated Abs followed by streptavidin-Tricolor
(Caltag Laboratories, Inc., South San Francisco, CA), and analyzed
with a FACScan
 
Ò
 
 (Becton Dickinson, San Jose, CA). mAbs were
against mouse CD8 (clone 53-6.7), CD4 (clone GK1.5), TCRV
 
b
 
11
(clone KT11), CD44 (clone IM-7), IL-2R (clone 7D4), L-selec-
tin (clone MEL-14), and macrophages/monocytes (clone F4/80
or clone M1/70). The Abs were prepared from hybridoma cell
lines or purchased from PharMingen (San Diego, CA).
 
Cytotoxicity Assay.
 
Ex vivo cytolytic activities in BAL were
tested directly in a standard cytotoxicity assay as described (31,
38). BAL cells obtained from two mice were pooled before being
assayed directly on EL-4 (H-2
 
b
 
) target cells infected with virus or
loaded with a synthetic peptide (amino acids 366–374 NP of A/
NT/60/68), in a 5-h cytotoxicity test. Tg-CTLs from the same
sample were detected directly by flow cytometric analysis, and
percentages of specific lysis were calculated at the highest Tg-
CTL to target cell ratio.
 
Treatment with Anti–IFN-
 
g
 
 mAb.
 
F5–RAG-1
 
2
 
/
 
2
 
 mice infected
with influenza A virus intranasally were injected intraperitoneally
with XMG1.2 anti–IFN-
 
g
 
 mAb (2 mg/mouse; donated by Dr.
P.C. Doherty, St. Jude Children’s Research Hospital, Memphis,
TN [39]), starting 1 d before infection and continuing every other
day throughout the experiment. Protocols using the same mAb
concentration and conditions have been shown to sufficiently
neutralize the antiviral effects of IFN-
 
g
 
 in vivo (40, 41).
 
Histology.
 
Lung tissues fixed in 10% buffered formalin were
paraffin embedded and sectioned. Each lung specimen was
stained with hematoxylin and eosin, and subjected to gross and
microscopic pathologic analysis.
 
Results
 
Protection against Influenza Virus Is Associated with 
Activities of Antiviral Abs, Whereas CTL Responses Play a 
Peripheral Role in Local Immunity
 
Intranasal administration of 
 
#
 
10
 
6
 
 PFU of A/NT/60/68
of influenza A virus to F5-Tg mice resulted in a pulmonary
infection and associated pathology that was regularly re-
solved within 2 wk (Fig. 1, 
 
A
 
, 
 
E
 
, and 
 
I
 
). Viral replication
peaked between days 2 and 4, followed by a rapid decline
in virus lung titers by day 8. This correlated with increased
levels of serum IgM and IgG antiviral Abs. Note that F5-Tg
mice contain considerable numbers of mature CD4
 
1
 
 Th cells
selected in the thymus via endogenous TCR 
 
a
 
 chains (due
to less stringent allelic exclusion) and that production of IgG
requires interaction of B cells with virus-specific CD4
 
1
 
 T
cells (31, 42, 43). Inoculation of a high dose (10
 
7
 
 PFU) of
A/NT/60/68 caused rapid spread of virus in the lung;
 
z
 
40% of the animals died (Fig. 1 
 
A
 
). Tg-CTLs isolated by
BAL and from tissues of the pulmonary-associated lym-
phatic system were capable of recognizing and lysing virally
infected target cells, or cells pulsed with the Tg-CTL pep-
tide epitope in standard cytotoxicity assays (data not shown).
Maximal cytolytic activities correlated with reduction of vi-
rus in lungs by days 6–8. No evidence of Tg-CTL activation
was observed in cells obtained from spleen or non–pulmo- 
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nary-associated lymphatic system tissues tested directly in
CTL assay or by staining with activation markers (data not
shown). A similar course of infection was observed in con-
trol C57BL/10 (H-2
 
b
 
) inbred mice (Fig. 1, 
 
B
 
, 
 
F
 
, and
 
 J
 
). To
directly assess the contribution of antiviral CTLs in protec-
tion against influenza, F5-Tg mice were infected with the
X31 reassortant virus, which cannot be recognized by the
Tg-CTLs. When X31-infected F5-Tg mice were compared
with control C57BL/10 mice (Fig. 1, 
 
C
 
, 
 
G
 
, and 
 
K
 
, versus
 
D
 
, 
 
H
 
, and
 
 L
 
), no significant differences in survival rate, vi-
ral replication in lungs, or virus-specific Ab titers were ob-
served. The overall kinetics of virus decline differed slightly,
in that virus was detectable in F5-Tg mice until day 12.
These observations indicate that in the presence of antiviral
Abs, host CTLs specific for NP of influenza virus play only
a peripheral role in local immunity.
 
Do CTLs Protect a Host against Influenza Virus in the 
Absence of Protective Abs?
 
We next evaluated the role of CTLs in influenza viral in-
fection more stringently by assessing their immunoreactiv-
ity in the absence of antiviral Abs using RAG-1–deficient
F5 mice (F5–RAG-1
 
2
 
/
 
2
 
). The repertoire of peripheral
lymphocytes of these mice consists only of Tg-CTLs (31).
F5–RAG-1
 
2
 
/
 
2
 
 and RAG-1
 
2
 
/
 
2
 
 (the latter lacking both B
and T cells) control mice were inoculated intranasally with
varying doses of A/NT/60/68 or X31 influenza virus, and
CTL functions were examined in the following ways.
 
CTLs Confer Protection or Contribute to Influenza Pathology
Depending on the Magnitude of Pulmonary Viral Load.
 
The
ability of CTLs to limit the severity of acute lung infection
was evaluated by measuring survival of F5–RAG-1
 
2
 
/
 
2
 
mice after infection with A/NT/60/68 (Fig. 2, 
 
left
 
). At the
highest dose given (10
 
7
 
 PFU), all mice died between days 2
and 6 (Fig. 2 
 
A
 
, 
 
left
 
). A progressive delay in the time of
death and increased survival rate were observed when viral
inoculum was decreased (Fig. 2, 
 
B
 
–
 
E
 
), with complete pro-
tection observed at 
 
#
 
10
 
4
 
 PFU. All control RAG-1
 
2
 
/
 
2
 
mice infected with A/NT/60/68 succumbed to viral dis-
ease (0% survival; Fig. 2, 
 
left
 
). Similarly, all F5–RAG-1
 
2
 
/
 
2
 
and RAG-12/2 mice infected with X31 died during the
Figure 1. Protection of mice against influenza A virus infection was
observed by reduction of viral titers in lungs and survival rate, correlating
with levels of antiviral Abs. F5-Tg or C57BL/10 control mice were in-
fected with A/NT/60/68 (A and B, E and F, and I and J) or X31 (C and
D, G and H, and K and L) influenza A viruses. (A–D) Mice were infected
with 107 PFU (filled circles) or #106 PFU (filled triangles) of influenza A vi-
rus, and percent survival is shown for groups of 10–15 mice. (E–H) Titer
of antiviral IgG (open circles) or IgM (filled circles) in serum of mice infected
with 106 PFU of influenza A virus was determined. Values shown for Ab
activity are mean log (ELISA titer) 6 SEM of three mice. (I–L) Virus in
lungs was measured in separate groups of mice infected with 106 PFU of
influenza A virus. The virus titer is shown as mean log10 TCID50 per
gram of lung 6 SEM of three to five mice.
Figure 2. In the absence of protective antiviral Abs, CTLs in the lung
tissue conferred protection against low viral challenge, but exacerbated
disease at high viral doses. F5–RAG-12/2 ( filled circles) or RAG-12/2
(open circles) mice were infected with A/NT/60/68 (left) or X31 (right) in-
fluenza A viruses. Percent survival is shown for groups of 10–15 mice.
The virus was administrated intranasally at a dose of (A) 107, (B) 106, (C)
105, (D) 104, or (E) 102 PFU. Percent survival was significantly greater in
F5–RAG-12/2 mice infected with 107 (P ,0.0001 by Wilcoxon test) or
105 PFU (P ,0.0001) of A/NT/60/68 than in control infected RAG-12/2
mice (A and B, left). No significant differences (P .0.09) were observed
between the same strains of mice infected with X31 (A and B, right).226 Role of CD81 CTLs in Influenza Virus Infection
first 20 d, with comparable kinetics (Fig. 2, right). The fact
that F5–RAG-12/2 mice infected with 107 PFU of A/NT/
60/68 died significantly faster (days 2–6; P ,0.0001 by
Wilcoxon test) than RAG-12/2 mice (days 6–24) but sur-
vived a relatively low dose of infection (#104 PFU) sug-
gests that, depending on the magnitude of pulmonary viral
load, CTLs can either confer protection or contribute to
pathology in influenza virus infection.
Protection against Influenza Virus or Lethal Viral Pathology
Are Related to the Success or Failure of CTLs to Control the Vi-
ral Infection. Susceptibility to influenza virus, often lethal
for mice, is closely associated with progressive pulmonary
viral infection. Therefore, comparative studies with F5–
RAG-12/2 and RAG-12/2 infected mice were performed,
correlating survival rate (Fig. 2) with virus titers in lungs
(Fig. 3). Kinetic profiles of viral replication in the lungs
were determined by measuring maximal viral titers and vi-
rus clearance rates (Fig. 3, A–D). Protection (increased sur-
vival; see Fig. 2) against influenza virus correlated with
lower maximal levels and rapid decline in viral titers. Thus,
F5–RAG-12/2 mice infected with A/NT/60/68 were pro-
tected only if they controlled viral replication (Fig. 3, C and
D, left). In contrast, high viral lung titer was seen in mice that
succumbed to infection (compare Figs. 2 A and 3 A). 104
PFU intranasal (i.n.) of A/NT/60/68 was a critical dose;
about one fourth of the infected mice failed to clear the vi-
rus and died, whereas the rest of the mice eliminated the
virus and were protected (compare Figs. 2 C and 3 B). The
experiments in this section suggest that CTLs confer pro-
tection against influenza by blocking in situ viral replica-
tion. Their failure to control viral infection is closely asso-
ciated with fatal disease.
Characterization of Transgenic CTLs in Lung Tissue under
Conditions of a Low versus High Viral Challenge. The pheno-
type and functional status of the inflammatory cells recov-
ered by BAL from F5–RAG-12/2or RAG-12/2 mice were
examined (Fig. 4). Under all conditions tested, primary in-
flammatory reactions were similar, consisting mainly of
macrophages/monocytes (positive for F4/80 and Mac-1a
antigen; data not shown). The total number of cells recov-
ered by BAL (Fig. 4, open symbols) increased rapidly (days
2–5) and peaked between days 4 and 8 with maximal val-
ues that correlated with the dose of infection. However,
transgenic CTLs (Vb111CD81; Fig. 4, filled symbols) were
found only in F5–RAG-12/2 mice infected with A/NT/
60/68 (Fig. 4, A–C). The kinetics of appearance of trans-
genic CTLs in the lungs revealed that transgenic CTLs
were detected earlier in mice infected with 107 PFU (day 2)
than with 104 or 102 PFU (days 3–5). This difference was
confirmed in two further experiments (our unpublished
observations). Transgenic CTLs isolated on days 2–16 from
lungs of mice infected with different doses of A/NT/60/68
and analyzed by flow cytometry were blast-sized and dis-
played activation status profiles (upregulation of IL-2R and
CD44 antigen and downregulation of L-selectin) compared
with naive transgenic CTLs (data not shown). As expected,
Figure 3. CTLs are protective against lethal influenza if they are able to
control viral replication in lung tissue at the onset of viral infection. Virus
titers in lung tissue of F5–RAG-12/2 (filled circles) or RAG-12/2 (open cir-
cles) mice infected with A/NT/60/68 (left) or X31 (right) influenza A vi-
ruses are expressed as mean log10 TCID50 per gram of lung of three to
five mice. Mice are infected intranasally at doses of (A) 107, (B) 105, (C)
103, or (D) 10 PFU.
Figure 4. Kinetics of total in-
flammatory cells versus trans-
genic CTLs in BAL of mice in-
fected with influenza A virus.
F5–RAG-12/2 mice were in-
fected intranasally with (A) 107,
(B) 104, or (C) 102 PFU of A/
NT/60/68, or with (D) 107 PFU
of control X31 virus (squares). In
addition, (D) RAG-12/2 mice
infected with 107 PFU of A/
NT/60/68 were included as
controls (triangles). The numbers
of inflammatory cells in BAL
(open symbols) are indicated as
mean  6 SEM log10 per lung of
three to five mice. BAL samples
(total volume 1 ml per lung)
containing  ,104 cells per ml (the
limit of detection of our
hemocytometer counting assay)
were estimated as 104 cells per
lung. Tg-CTLs (filled symbols)
were detected in the same sam-
ples by staining cells with Abs
specific for Vb11, CD8 and
analysis by flow cytometry. Ab-
solute numbers of Tg-CTLs
were calculated as percent transgenic positive cells by flow cytometry
multiplied by total cell number. Populations ,1% were considered unde-
tectable.227 Moskophidis and Kioussis
CTLs were efficient in lysing target cells loaded with rele-
vant viral peptide (A/NT/60/68 NP-366-374). Thus, cells
obtained by BAL from two mice were pooled and assayed
directly on EL-4 (H-2b) target cells loaded with peptide in
a cytotoxicity assay, and percentages of specific lysis were
calculated at highest transgenic CTL to target cell ratio.
The lytic activity in F5–RAG-12/2 mice infected with 107
PFU of A/NT/60/68 was 15% (day 4, ratio 2:1), 30% (day
5, ratio 12:1), and 50% (day 8, ratio 25:1) compared with
animals infected with 102 PFU, which exhibited 10% (day
5, ratio 4:1), 25% (day 8, ratio 12:1), and 60% (day 12, ratio
25:1). The same effector cells tested on unloaded target
cells displayed cytotoxicity ,2% at the highest E/T ratio.
In addition, lytic activity in BAL from control F5–RAG-
12/2 mice infected with X31, or from RAG-12/2 mice in-
fected with A/NT/60/68, was undetectable (,2%). Thus,
transgenic CTLs in lungs of mice that succumbed to lethal
influenza were functionally active. Control F5–RAG-12/2
mice infected with X31, or RAG-12/2 mice infected with
A/NT/60/68 or X31, developed a progressive pulmonary
inflammation, but transgenic CTLs were undetectable (Fig.
4 D, and data not shown). Finally, because of the short
time span between appearance of transgenic CTLs in lungs
and lethal outcome of viral disease (2–4 d), it is unlikely
that transgenic CTL escape variants in infected mice are re-
sponsible for these results (44, 45). Likewise, our findings
are not compatible with anergy (46–49) or clonal deletion
of transgenic CTLs (50, 51) as possible mechanisms for the
inability of F5–RAG-12/2 mice to control infection with a
relatively high dose of A/NT/60/68.
Morphological Representations of CTL Activities In Vivo.
It is likely that the characteristics of cells obtained by BAL
do not fully reflect the overall pulmonary inflammatory
process. Therefore, lung tissue from control (uninfected) or
virus-infected mice were analyzed histologically (Table 1).
Hematoxylin and eosin–stained paraffin sections of lungs
showed that the general course of lung pathology of F5–
RAG-12/2 mice infected with A/NT/60/68 was partially
influenced by the rate of pulmonary viral spread, but to a
greater extent was determined by antiviral CTLs (Fig. 5).
Indeed, Tg-CTLs in lungs of mice with a restricted viral
infection (i.e., 102 PFU i.n.) tempered the severity of the
disease (Fig. 5 A). Lung pathology was confined to a few
foci of perivascular and peribronchial inflammation of
mononuclear cells (macrophages/monocytes), containing
numerous leukocytes/lymphoblasts. Although inflamma-
tion persisted beyond 2 wk, with gradual decline in magni-
tude, there was less evidence of epithelial necrosis and
desquamation of affected tracheobronchiolar mucosa. In
contrast, the activity of Tg-CTLs in lungs of mice with
progressive viral infection (i.e., 107 PFU i.n.) had deleteri-
ous consequences for the host (Fig. 5 B). The entire archi-
tecture of lung tissue became profoundly altered within a
few days as a result of extensive inflammation and edema,
with thickening of intraalveolar septa and loss of alveoli,
but with less evidence of hemorrhages. The pathologic
process in control RAG-12/2 mice (107 PFU of A/NT/
60/68) developed more slowly; there was less evidence of
pathologic alterations in lung tissues during the first week
of infection, and primary inflammatory reactions were con-
fined to a few foci of infiltrating cells. However, in the
course of infection the animals developed the characteristic
features of fatal viral pneumonia (edematous lung tissues,
congestion, and collapse of alveoli; data not shown). Lung
tissues of F5–RAG-12/2 mice infected with X31 (107
PFU; Fig. 5 C) show the characteristic features of a pro-
gressive fatal pneumonia as described for F5–RAG-12/2
mice infected with 107 PFU of A/NT/60/68. Lung tissues
of uninfected F5–RAG-12/2 mice were well aerated,
without evidence of infiltrates or pathologic alterations
(Fig. 5 D). Together, these results confirmed our initial ob-
servations suggesting a contribution of antiviral CTLs to
pulmonary pathology as a result of overwhelming influenza
viral infection.
Table 1. Extent of the Pulmonary Inflammatory Process of TCR-transgenic Mice Infected with Influenza A Virus
Mice Virus
Time after infection
Day 2 Day 5 Day 8 Day 15 Day 20
F5–RAG-12/2 A/NT/60/68, 107 PFU 11 1 1 1 *
A/NT/60/68, 102 PFU 211 6 6
X31, 107 PFU 11 1 1 1 *
RAG-12/2 A/NT/60/68, 107 PFU 6 1 11 11 11
X31, 107 PFU 11 1 1 1 *
11, Intensive pathology with cell inflammation encompassing several segments of lung tissues. Development of extensive lung edema and conges-
tion. Thickened intraalveolar septa and loss of alveoli.
1, Inflammatory reaction consisting of a few foci of peribronchiolar and perivascular infiltrates on medium and small airways. There was modest ev-
idence of epithelial necrosis of affected tracheobronchiolar mucosa.
6, Lung tissue with a few infiltrates. No epithelial necrosis or desquamation.
2, Lung tissue well aerated. No infiltrates or pathologic alteration of lung tissue.
*, At the indicated time, all mice had died.228 Role of CD81 CTLs in Influenza Virus Infection
Effects of In Vivo Administration of Anti–IFN-g mAb on 
the Mediation of Lethal and Sublethal Influenza by Antiviral 
CD81 CTLs
To further define the mechanism(s) of virus-specific
CD81 T cell–mediated clearance or enhancement of in-
flammation, the effects of parenterally administrated anti–
IFN-g were examined. Although all F5-RAG mice in-
fected with a high dose of A/NT/60/68 (107 PFU) died
between days 2 and 6, a delay in the time of death and in-
creased survival rate (z50%) were observed when infected
animals were treated with anti–IFN-g mAb throughout the
experiment (Fig. 6 A). Surprisingly, treated animals com-
pletely cleared virus from lung parenchyma by day 8 (Fig. 6
C). In contrast, control untreated infected mice were un-
able to eliminate the virus; however, significantly reduced
viral lung titers were measured by day 6 and were main-
tained until the mice succumbed to infection (Fig. 6 C), in-
dicating that antiviral CD81 T cells were only partially effi-
cient in controlling the infection. Treatment of mice with
anti–IFN-g mAb had no effect on the kinetics or magni-
tude of the effector Tg-CTL response in the lung paren-
chyma (Fig. 6 E). Identical total numbers of inflammatory
cells were found in the BAL of anti–IFN-g–treated mice
and control mice (Fig. 6 G). However, histological analysis
of the lung tissues revealed a restricted pattern of inflamma-
tion and significantly reduced pathologic features of pneu-
monia in the early stages of infection, with gradual decline
in magnitude after anti–IFN-g mAb treatment in compari-
son with control virus infected mice (data not shown). In
mice given a sublethal dose of 102 PFU of influenza virus,
blockade of IFN-g had little effect on lethality, elimination
of pulmonary virus, or kinetics and magnitude of Tg-CTL
response in the lung parenchyma (Fig. 6, B, D, F, and H).
Discussion
Many studies have demonstrated a major role for CD81
CTLs in control of viral infection. However, it has been
difficult to follow development of the specific CTL re-
sponses in situ in infected tissues. Here we report an inno-
vative approach, using transgenic TCR mice specific for
influenza virus (F5) and mice deficient in CD41 and B cells
(F5–RAG-12/2), which allows the monitoring of specific
CD81 CTL responses directly in situ. This powerful tool
provides a unique opportunity to study the in vivo fate, ef-
fector functions, and interactions of virus-specific CTLs in
the lung tissue.
The results reported here elucidate some basic principles
by which host CTLs amplify defenses against influenza vi-
rus. First, effector CTLs localized to sites of virus infection
Figure 5. Histological examination of lung tissue. Lungs were taken on day 6 or 8 from F5–RAG-12/2 transgenic mice infected with (A) 102 PFU of
A/NT/60/68, (B) 107 PFU of A/NT/60/68, or (C) 107 PFU of X31 influenza A virus. (D) Lung tissue of a control uninfected F5–RAG-12/2 mouse.229 Moskophidis and Kioussis
can have either beneficial or harmful effects on the infected
host. In the absence of protective Abs, CTLs can potently
block viral replication conferring protection against influ-
enza virus, or they can contribute significantly to the gene-
sis and progression of fatal disease. CTL-mediated effects
are related to the magnitude of ongoing pulmonary viral
infection, whereby the timing of CTL appearance in lung
tissues seems to be the most critical factor. This dramatic
example of CTL-mediated opposing effects (protection
versus lethal pathology) during influenza virus infection
adds to reports that CTLs may aggravate disease in viral in-
fections (52–56). Second, the primary driving force under-
lining influenza pathology is the virus. Thus, unrestricted
viral dissemination in lungs results in fatal pulmonary dis-
ease. The results of this study do not support the theory
that pulmonary pathology is due to the intrinsic cytopathic
effects of the virus. However, neither do the data suggest
an “innocent bystander” role for the virus. In contrast, viral
replication in the lungs is accompanied by an inflammatory
process that is probably initiated by chemokines released
from infected cells. These chemokines then attract inflam-
matory cells to the site of infection. Third, our studies are
indicative of the dynamic process underlying the develop-
ment of influenza viral CTL responses (57). Several lines of
evidence suggest that the disease process is terminated rap-
idly if effector CTLs appear in the lungs before or very
early after the onset of infection (8, 58–62). Our results
suggest that this situation will be difficult to achieve by vac-
cination strategies aimed at increasing the frequency of an-
tiviral CTL precursors. In support of this view, it has been
found that both virgin and primed CTLs need a span of
4–5 d to become potent CTL effectors (7, 58, 63). Thus, the
protective ability of CTLs is restricted to a delicate equilib-
rium between their effector activities and viral load in the
lungs. Protective Abs recognizing minor changes in surface
proteins within an influenza subtype may shift this balance
by slowing down virus replication (and thus reducing viral
load) in the onset of infection, thereby allowing CTLs to
rapidly terminate viral replication in lungs. This may offer a
simple explanation for why CTLs are not capable of pre-
venting influenza epidemics, but on the other hand seem to
provide limited protection from clinical disease (8, 64).
Multiple mechanisms may contribute to the protective
and pathogenic effects shown by antiinfluenza CTLs. It is
important to distinguish the role of soluble factors and cy-
tokines, as well as possible qualitative differences in the CTLs
themselves. Such information will be essential for develop-
ing a better understanding of viral pathogenesis and a more
rational approach to therapeutic intervention in influenza
and other respiratory viral infections. CD81 T cells have
been shown to mediate an in vivo antiviral effect either via
direct lysis of infected host cells, or by release of cytokines
that induce an antiviral effect (65, 66). The ultimate impact
of these CD81 T cell–mediated effector mechanisms on
elimination of and recovery from influenza A virus infec-
tion, and on the outcome of pulmonary disease, is not well
defined.
Regarding effector mechanisms used by CD81 T cells in
clearance of influenza virus, a recent study by Topham et al.
using radiation chimeras suggested that target cell destruc-
tion mediated via Fas or perforin pathways is probably the
primary mechanism used by CD81 CTLs in clearance of
the virus (67). On the other hand, studies with immuno-
competent mice deficient in production of IFN-g either by
targeted gene disruption or parenteral administration of a
neutralizing anti–IFN-g Ab into mice lacking b2-micro-
globulin (the latter lack CD81 T cells) indicated a less im-
portant role for IFN-g in the clearance of influenza virus
infection (39, 68). However, the data do not exclude the
Figure 6. The effect of administration of anti–IFN-g on mortality,
elimination of pulmonary virus, and numbers of Tg-CTLs versus total cell
counts in the BAL of influenza virus–infected F5–RAG-12/2 mice. F5–
RAG-12/2 mice were infected intranasally with a lethal dose of 107 PFU
(left) or a sublethal dose of 102 PFU (right) of A/NT/60/68. Mice were
treated with anti–IFN-g mAb (filled circles) as described in Materials and
Methods, or with PBS as control (open circles). (A and B) Percent survival
is shown for groups of 5–10 mice. (C and D) Virus titers in lung tissue
were expressed as mean log10 TCID50 per gram of lung of three to five
mice. (E and F) Tg-CTLs were detected in the same samples by staining
cells with Abs specific for Vb11, CD8 and analysis by flow cytometry,
and were expressed as mean 6 SEM log10 per lung of three mice. (G and
H) The numbers of inflammatory cells in BAL were indicated as mean 6
SEM log10 per lung of three mice.230 Role of CD81 CTLs in Influenza Virus Infection
possibility that there may be some biologic redundancy in
the immune response to influenza, and that other effector
mechanisms (e.g., Abs) may influence the degree to which
IFN-g is required for prompt resolution of infection. The use
of F5–RAG-12/2 mice provides an opportunity to address
this issue more directly. The results reported here are in agree-
ment with and extend the above findings. Although IFN-g
appears be nonessential for CD81 T cell–mediated recovery
from a sublethal influenza virus infection, this study shows
clearly that it exerts a marked effect on the outcome of lethal
infection. Thus, treatment of F5–RAG-12/2 mice with anti–
IFN-g mAb during a sublethal or lethal influenza infection
had no effect on the kinetics or magnitude of effector CTL
responses in the lung. However, it seems that IFN-g secreted
in high levels by activated Tg-CTLs does contribute to mor-
tality after infection of F5–RAG-12/2 mice with a lethal dose
of the virus. The most likely explanation for this effect is that
Tg-CTLs release IFN-g upon contact with infected MHC
class I–positive cells. This results in increased vascular perme-
ability (69), and promotes the development of massive lung
edema and leukocyte migration and/or retention into lung
parenchyma. Support for this hypothesis is provided by
earlier observations showing that IFN-g may also act as a
typical inflammatory cytokine, which influences the overall
increase in the number of cells found in the lung paren-
chyma but has no effect on either the preferential accumu-
lation of CD81 T cells or their cytolytic effector function
(70). Our findings of reduced viral pathology in anti–IFN-
g–treated mice, despite the fact that the numbers of inflam-
matory cells in BAL were not different in comparison with
control untreated mice, strengthen this concept. Thus,
neutralization of IFN-g during onset of viral infection may
ameliorate the course of disease, allowing Tg-CTLs to clear
the virus from the lung. It is also conceivable that IFN-g
acting as an immunomodulator increases MHC class I ex-
pression on virally infected cells and therefore promotes pa-
thology based on cytodestructive Tg-CTL effects. Experi-
ments with mice deficient in the CTL cytolytic pathways
(perforin or Fas antigen) could directly address this issue.
In conclusion, our data suggest that suppression of virus
replication in the early phase of infection is the most im-
portant feature in prevention of influenza virus disease. The
challenge in creating a CTL-based vaccine (71–77) directed
against heterosubtypic influenza virus strains is to raise the
abundance of CTL precursor cells early in the infection in
order to increase the protective response without exacer-
bating a pathology that is also CTL dependent. Finally,
evaluation of the dynamic equilibrium established between
the CTL immune response and viral infection is obviously
a prerequisite for a better understanding of influenza patho-
genesis, since inappropriate CTL activation intensifies the
pathologic process (55, 78, 79).
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